Zealand Pharma A/S is a Denmark-based biotechnology company focused on the discovery, development, and commercialization of innovative peptide-based medicines. The Company's activities are organized around three therapeutic areas: Obesity and Related Comorbidities, which includes obesity and metabolic disease therapies; Rare Diseases, which develops treatments for congenital hyperinsulinism and short bowel syndrome; and Inflammation, which focuses on therapies for chronic inflammatory and autoimmune diseases. Zealand Pharma conducts research and development activities internally and through strategic collaborations with pharmaceutical partners, including Roche and Boehringer Ingelheim.
Back to dashboard
Company Information
About this company
Key people
Alf Gunnar Nicklasson
Independent Chairman of the Board
David M. Kendall
Chief Medical Officer, Head of Research and Development
Frederik Barfoed Beck
Director - Employee Representative
Anneline Nansen
Director - Employee Representative
Adam Krisko Nygaard
Director - Employee Representative
Adam Sinding Steensberg
President, Chief Executive Officer, Member of the Executive Management
Kirsten Aarup Drejer
Independent Vice Chairman of the Board
Henriette Wennicke
Executive Vice President, Chief Financial Officer, Member of the Executive Management
Ivan Moeller
Executive Vice President, Chief Operating Officer
Christina Sonnenborg Bredal
Chief People Officer, Executive Vice President
Utpal Singh
Executive Vice President, Chief Scientific Officer
Eric Cox
Executive Vice President, Chief Commercial Officer
Steven Johnson
Executive Vice President, Chief Development Officer
Click to see more
Key facts
- Shares in issue71.58m
- EPICZEAL
- ISINDK0060257814
- LocationDenmark
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market capDKK 22.30bn
- Employees578
- ExchangeCopenhagen Stock Exchange
- IndexDenmark-OMX-Copenhagen-All-Share-Index, TR Equity Denmark Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.